NEW YORK, July 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Group 1 - The WisdomTree Cybersecurity Fund ETF (NASDAQ: WCBR) targets investors seeking exposure in the rapidly growing cybersecurity industry [1] - The cybersecurity market is projected to experience significant growth over a long-term horizon [1] Group 2 - The article emphasizes the importance of informed investment decisions and aims to share insights and analysis with a global audience [1]

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, which is administered at authorized treatment centers (ATCs) [3]. Group 2: Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Group 3: Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Insights - Merus N.V. (MRUS) shares have increased by 29.9% over the past three months, driven by positive interim results from a phase II study of its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck's Keytruda for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][4] Study Results - As of February 27, 2025, 45 patients were treated, with 43 deemed efficacy-evaluable, resulting in a confirmed overall response rate (ORR) of 63%, which included six complete responses and 21 partial responses [2] - The ORR varied with PD-L1 expression levels, showing a 73% ORR in patients with a combined positive score (CPS) greater than 20 and 47% in those with CPS 1–19 [2] - Median progression-free survival was reported at nine months, with an overall survival rate of 79% at 12 months [3] Safety Profile - The safety profile of the combination therapy was manageable, with no significant overlapping toxicities reported with Keytruda; treatment-related adverse events occurred in all patients, with infusion-related reactions observed in 38% [5][6] Future Prospects - The promising data suggests that the petosemtamab combination therapy could become a new standard of care for HNSCC, a cancer type with poor prognosis [6] - Merus is also conducting a registrational phase III study (LiGeR-HN1) for the combination therapy and another study (LiGeR-HN2) for petosemtamab monotherapy [7][8] Market Context - Merck's Keytruda, a leading anti-PD-1 therapy, generated $7.21 billion in sales in Q1 2025, reflecting a 6% year-over-year increase, and continues to expand into new indications and markets [8][10]

对国产GPU企业而言，"资本热捧"是故事的A面。 "主权AI"定义下的未来，既是技术竞赛，也是资本竞赛。对于 需要海量资金投入的中国GPU（图形处理器）追赶者而言，黄 仁勋的话语让它们奔赴二级市场、寻求"弹药"的动作显得尤为 迫切。 作者：郑晨烨 美编：赵刈 2025年7月9日，美股上市公司英伟达（NASDAQ：NVDA）市值盘中首次突破4万亿美元，超过微 软和苹果，成为全球股票史上市值最大的上市公司。 在英伟达创始人黄仁勋的叙事中，AI已经成为一场新工业革命的开端。他在COMPUTEX 2025大 会的演讲中反复强调，计算的产生方式已经发生根本性变化，每个国家都需要拥有自己的AI， 即"主权AI"。 "主权AI"定义下的未 来， 既是技术竞赛，也是资本竞赛。 对于需要海量资金投入的中国GPU （图形处理器）追赶者而言，黄仁勋的话语让它们奔赴二级市场、寻求"弹药"的动作显得尤为迫 切。 6月30日，摩尔线程智能科技（北京）股份有限公司（下称"摩尔线程"）与沐曦集成电路（上海） 股份有限公司（下称"沐曦股份"）同时向上交所递交了招股说明书。加上已在科创板上市的寒武纪 （688256.SH），国产GPU赛道最受瞩 ...

Core Viewpoint - Nvidia's market capitalization has reached $4 trillion, making it the largest publicly traded company in history, which has created significant investment opportunities for domestic GPU manufacturers in China [2][3]. Group 1: Market Dynamics - The concept of "sovereign AI" emphasizes the need for each country to develop its own AI capabilities, leading to a competitive landscape where capital investment is crucial for Chinese GPU companies [2]. - The surge in Nvidia's valuation has prompted a wave of IPOs among domestic GPU firms, as investors seek companies that can rival Nvidia [5][17]. - The financial performance of domestic GPU companies is concerning, with significant losses reported over recent years, highlighting the challenges they face in achieving profitability [8][9]. Group 2: Financial Performance - Moer Technology reported net losses of approximately 50 billion yuan from 2022 to 2024, with R&D expenses totaling 38.1 billion yuan against revenues of only about 6 billion yuan [8]. - Similarly, Nuxi Technology has accumulated losses of 32.90 billion yuan from 2022 to the first quarter of 2025, with R&D investments far exceeding total revenues [8]. - Cambrian, another player in the market, has also faced substantial losses, exceeding 33 billion yuan since its IPO in 2020 [9]. Group 3: Investment and Valuation - The valuation logic in the market has led to speculative estimates, such as Cambrian being valued at 1% of Nvidia's market cap based on its potential to become a Chinese equivalent [5]. - Early investors are betting on the potential of these companies to replicate the success of international giants, given the strong backgrounds of their founders [7][6]. Group 4: Customer Dependency and Revenue Quality - Domestic GPU companies are heavily reliant on a small number of clients, with Moer Technology's top five customers accounting for over 98% of its revenue in recent years [20]. - The instability in customer relationships poses risks, as seen in Nuxi Technology's rapidly changing client base, which reflects a lack of long-term partnerships [24]. - The revenue generated from system integration and large clients raises questions about the sustainability and quality of income for these companies [19][21]. Group 5: Supply Chain and Production Challenges - The reliance on external supply chains for chip production introduces risks, particularly as some companies face restrictions on accessing advanced manufacturing processes [30]. - The financial burden of chip design and production, including high "tape-out" costs, adds to the financial strain on these companies [15][16]. Group 6: Future Outlook and Strategic Considerations - The future success of domestic GPU firms may hinge on their ability to secure funding and develop competitive products that can match or exceed the performance of established players like Nvidia [32][33]. - There is a debate within the industry regarding whether the focus should be on securing financing or on building a sustainable business model that emphasizes product performance and market fit [31][32].

Core Viewpoint - The WisdomTree Multi Asset Issuer Public Limited Company is proposing an amendment to the principal amount of its WisdomTree Brent Crude Oil 3X Daily Short Securities due to a significant decline in their value, necessitating a reduction from USD 0.114 to USD 0.0114 [4]. Group 1: Meeting Details - The original meeting scheduled for July 11, 2025, was adjourned due to a lack of quorum and will be reconvened on August 1, 2025 [3]. - The adjourned meeting will take place at the offices of Apex IFS Limited in Dublin, Ireland [3]. Group 2: Proposal and Voting Instructions - The purpose of the adjourned meeting is to consider amendments to the documentation required for the proposed reduction in the principal amount of the affected securities [4]. - Holders of the affected securities must submit new voting instructions for the adjourned meeting, as previous instructions from the original meeting will not be valid [5]. - It is advised that holders check with their intermediaries regarding deadlines for submitting instructions to participate in the adjourned meeting [6][7]. Group 3: Trustee's Position - The Law Debenture Trust Corporation p.l.c., as trustee, has no objection to the proposal's presentation but does not express an opinion on its merits [8]. Group 4: Notification of Outcome - Holders of the affected securities will be informed of the outcome of the adjourned meeting shortly after it concludes [9].

[ 哪些车在使用"消费级芯片"？ ] 小米YU7上市后的第一个舆论场出现在对于"车规级"的讨论，YU7的座舱芯片用了消费级的高通8gen3，相比之下无关痛痒的纸巾盒却是车规级，被网友 疯狂调侃"人走盒在"。 实际上，小米YU7并不是第一个使用非车规级芯片的车型，特斯拉早在近十年前就开始了尝试，但也曾因芯片过热失效而大范围召回。 YU7的爆卖，又一次把这个话题推到了风口浪尖上——由消费级芯片控制座舱的智能汽车，到底能不能买？ 省流版：拉到结尾直接看结论。 NO.1 车规级实际上是一种全生命周期的质量管理理念，从产品设计、测试、量产，到变更管理，这是一个系统性工程。 常见的芯片等级一般是按照使用温度、辐射、抗干扰等因素，标准从宽泛到严格分为5类，即消费级、工业级、车规级、军工级、航天级。 在汽车产业，同济大学汽车学院教授朱西产对汽车产经表示，一辆汽车约1000多张芯片，芯片所在的部件功能不同，对于影响人身财产的功能安全的部 件，所用芯片肯定要做AEC-Q100和ISO26262功能安全认证，这就是我们说的"车规级芯片"。 但对于不涉及功能安全的部件，所用的芯片只需要AEC-Q100耐环境能力测试和寿命测试就够了。 ...

Core Insights - BriaCell Therapeutics Corp. announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, showing a significant survival advantage in heavily pretreated metastatic breast cancer patients [1][2]. Survival Data Analysis - The Phase 2 study demonstrated that the median overall survival (OS) for triple-negative breast cancer (TNBC) patients treated with Bria-IMT plus CPI was 13.9 months, surpassing Trodelvy's 11.8 months and single-agent chemotherapy's 6.9 months [3][4][5]. - For hormone receptor-positive (HR+) metastatic breast cancer patients, the median OS with Bria-IMT plus CPI was 17.3 months, exceeding Trodelvy's 14.4 months and single-agent chemotherapy's 11.2 months [4][5]. - The study included 54 heavily pretreated metastatic breast cancer patients, with a median of six prior therapies, and no treatment-related discontinuations were reported [7]. Comparison with Established Treatments - Bria-IMT's performance in TNBC and HR+ patient subtypes outperformed established benchmarks, indicating a potential clinical impact of the novel immunotherapy [2][4]. - The survival rates at 6 months for TNBC patients were 78% for Bria-IMT plus CPI compared to 80% for Trodelvy and 56% for single-agent chemotherapy [3]. - For HR+ patients, the survival rates at 6 months were 90% for Bria-IMT plus CPI, compared to 83% for Trodelvy and 76% for single-agent chemotherapy [3]. Future Outlook - The company is looking forward to validating these findings in its ongoing pivotal Phase 3 study, which has overall survival as its primary endpoint [2][6].